Brief: Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
04/03/2025 21:54
March 4 (Reuters) - Contineum Therapeutics Inc CTNM.O: CONTINEUM THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1B CHRONIC PAIN TRIAL OF PIPE-791 CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 PHASE 1B TRIAL EXPECTED IN EARLY 2026 Source text: ID:nBwbMmCNpa Further company coverage: CTNM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Contineum Therapeutics
See all newsPREVIEW: Johnson & Johnson earnings expected to decline in Q3
PREVIEW: Johnson & Johnson earnings expected to decline in Q3
US STOCKS ON THE MOVE-Microsoft, Salesforce, Bristol Myers
US STOCKS ON THE MOVE-Microsoft, C3.ai, Salesforce, Bristol Myers
Contineum tumbles as Bristol's partial trial win raises dose doubts